The FDA peptide vote on July 23 and 24, 2026 marked the first time a federal advisory committee formally backed research peptides like BPC-157 and TB-500 for compounding. The Pharmacy Compounding Advisory Committee recommended six of the seven peptides it reviewed for the 503A Bulks List. FDA staff had recommended against all seven.
That split is the headline. It is also easy to misread. A favorable vote sounds like approval, and it is not. Here is what the committee actually decided, what still has to happen, and what the FDA did in the weeks that followed.
The 503A Bulks List is the roster of raw ingredients that licensed compounding pharmacies are allowed to work with. If a substance is not on that list, not part of an FDA approved drug, and not covered by an official pharmacopeia standard, a 503A pharmacy cannot use it. Think of it as a guest list. The committee was voting on who gets added.
Seven peptides came up for review across two days. The committee voted in favor of BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax. It voted against emideltide, also known as DSIP. Several votes were close, and each peptide was reviewed against specific proposed clinical uses rather than as a blanket endorsement.
The road here started in February, when HHS Secretary Robert F. Kennedy Jr. announced that most of the peptides on the FDA’s Category 2 restricted list would be moved back. In April, the agency removed a group of peptides from Category 2 and scheduled them for committee review. We covered that phase in the FDA peptide reclassification: what actually changed in 2026. The July meeting was the next step in that process.
For the research background on two of the compounds that cleared the vote, see our BPC-157 research overview and TB-500 research overview.
The committee advises. The FDA decides. The votes do not change the 503A Bulks List on their own, and they do not make any of the six peptides compoundable today.
Adding a substance to the list requires notice and comment rulemaking. The FDA would first publish a proposed rule, open a public comment period, review the record, and then issue a final rule. Final approval also runs through the HHS Secretary. There is no statutory deadline for any of it, and past rounds of the bulks list have taken years to move from proposal to final rule.
As of mid-September, none of the six peptides appeared on the codified 503A Bulks List, and no proposed rule adding them had been published. A second committee meeting is scheduled before the end of February 2027 to review five more peptides.
It also helps to separate two markets that often get blurred together. The 503A pathway governs licensed pharmacies preparing medications. Peptides sold for laboratory use sit under a different framework entirely, covered in research use only explained. A compounding decision does not rewrite the rules for either one overnight. For the full legal picture, see are peptides legal in the United States.
One month after the vote, the FDA moved in the other direction on a different front. On August 24, 2026, the agency issued warning letters to five online peptide sellers, made public on September 1. The products named included GLP-1 compounds, tesamorelin, and ipamorelin blends.
The letters drew a clear line. Each seller labeled its products for research use, and the FDA said that labeling did not settle the question. The agency looked at the whole operation, including product descriptions, website content, and supplies sold alongside the peptides, and concluded the products were intended for human use. The sellers were given 15 days to respond.
Read together, July and August send one message. The FDA is open to a regulated pathway for certain peptides through licensed pharmacies. It is not softening its view of sellers whose marketing points toward human use. Both trends are reshaping which suppliers remain in the market, a shift we break down in why are peptide companies shutting down.
The next markers to watch are a proposed rule in the Federal Register and the February 2027 committee meeting. Until either arrives, the July vote is a recommendation on the record, not a change in the law.
To explore how peptides are studied and applied across research settings, visit our Research Library.
FDA advisory committee nominates six peptides for pharmacies to compound — NCPA, 2026
FDA Advisory Committee Voted Yes on Six Peptides. Now What? — Buchanan Ingersoll & Rooney, 2026
FDA committee recommends looser restrictions for several peptides — Healio, 2026
Warning Letter: Peptide Partners LLC — U.S. Food and Drug Administration, 2026